基于 DNA 超分子水凝胶的保护性 NK 细胞储库用于增强三阴性乳腺癌治疗
Protective NK Cell Reservoir Based on DNA Supramolecular Hydrogel for Enhanced Triple-Negative Breast Cancer Therapy.
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
英文原题:A lung specific escape of intravascular metastatic breast cancer cells from cytotoxic T cell killing.
A lung specific escape of intravascular metastatic breast cancer cells from cytotoxic T cell killing.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
肺是癌症转移的主要器官。尽管使用具有强效杀伤活性的肿瘤特异性细胞毒性T细胞(CTL)(即肿瘤浸润T细胞,TIL)杀伤原发肿瘤方面取得了进展,但这些T细胞如何遇到并杀伤远端器官的转移病灶仍知之甚少。
在本研究中,我们比较了强效新抗原特异性CTL杀伤两种癌细胞的能力,这两种癌细胞共享相同的新抗原,并在免疫功能正常的受体小鼠肺中形成不同的转移病灶。
我们使用卵清蛋白(OVA)作为新抗原模型,发现OVA特异性OT-I转基因CD8 CTL经静脉输入后,能够轻易清除表达OVA的乳腺癌E0771细胞的原发肿瘤。
然而,类似的OT-I CTL未能清除定植于肺部的表达OVA的乳腺癌E0771细胞。相比之下,类似经静脉输入的OT-I CTL能够有效清除肺转移的表达OVA的B16黑色素瘤细胞,排除了静脉输入的CTL在进入肺部后发生耗竭的可能性。全肺三维(3D)成像显示,在实验性和自发性转移模型中,OVA E0771细胞均存活于肺血管内,但未将循环中的OT-I CTL募集到其附近。
此外,CTL识别的经典血管黏附分子如ICAM-1和VCAM-1在肺内血管内E0771细胞附近未上调,而这可能是将肺循环CTL募集到血管内肿瘤细胞附近的一种潜在方式。引人注目的是,肺内驻留的表达OVA的E0771细胞丢失了其OT-I特异性OVA来源的SIINFEKL-H-2Kb pMHC复合物的表达,同时保留了MHC-I的表达。这种缺失伴随着肺特异性转录水平上MHC-I呈递关键调控因子的减少。
然而,将OVA来源的SIINFEKL-H-2Kb pMHC复合物暂时加载到E0771细胞上,并未导致癌细胞在肺内被杀伤。尽管如此,这些细胞上直接且稳定的SIINFEKL肽呈递克服了其肺特异性逃逸OT-I介导的杀伤。
我们的研究首次表明,驻留在肺部的癌细胞亚群会迅速下调新抗原来源肽-MHC-I复合物的表达,从而逃逸静脉注射的肿瘤抗原特异性CTL的杀伤。
The lungs are a major organ of cancer metastasis. Despite advances in the usage of tumor- specific cytotoxic T cells (CTLs) with potent killing activity (i. e. , tumor infiltrating T cells, TILs) for killing of primary tumors, how these T cells encounter and kill metastatic lesions at remote organs is still poorly understood.
In the present study we compared the ability of potent neoantigen specific CTLs to kill two types of cancer cells that share the same neoantigen and generate distinct metastatic lesions in the lungs of immunocompetent recipient mice.
We have used ovalbumin (OVA) as a neoantigen model and found that the OVA-specific OT-I transgenic CD8 CTLs, when intravenously introduced, readily eliminated primary tumors of OVA-expressing breast cancer E0771 cells. Nevertheless, similar OT-I CTLs failed to clear OVA-expressing breast cancer E0771 cells that colonized the lungs.
In contrast, similar intravenously introduced OT-I CTLs efficiently eliminated lung metastatic OVA-expressing B16 melanoma cells, ruling out that the intravenous CTLs were exhausted upon entering the lungs. Three-dimensional (3D) imaging of whole lungs revealed that in both experimental and spontaneous metastasis models, the OVA E0771 cells survived inside lung blood vessels but did not recruit circulating OT-I CTLs to their vicinity.
Furthermore, canonical vascular adhesion molecules recognized by the CTLs like ICAM-1 and VCAM-1 were not upregulated nearby the lung-residing intravascular E0771 cells as a potential means to recruit lung circulating CTLs to the vicinity of the intravascular tumor cells. Strikingly, the lung residing OVA-expressing E0771 cells lost expression of their OT-I specific OVA-derived SIINFEKL-H-2Kb pMHC complexes while retaining MHC-I expression.
This loss was accompanied by a lung-specific transcriptional reduction of key regulators of MHC-I presentation. A temporal loading of OVA-derived SIINFEKL-H-2Kb pMHC complexes on E0771 cells did not result, however, in cancer cell killing inside the lungs. Nevertheless, direct and stable SIINFEKL peptide presentation on these cells overcame their lung specific escape from OT-I mediated killing.
Our study is a first indication that subsets of cancer cells that reside in the lungs rapidly downregulate the expression of neoantigen derived peptide MHC-I complexes and thereby evade killing by intravenously introduced tumor antigen-specific CTLs.
在 PubMed 查看 → 出版商原文(DOI) 全文 PDF(PMC)· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →
MEMBER ACCOUNT
登录成功会直接打开下一页。